New insights into the biotransformation and pharmacokinetics of oxaliplatin.
Oxaliplatin is used primarily in the treatment of metastatic colorectal cancer. In this minireview, we discuss potentially important biotransformation pathways in light of its short elimination half-life in vivo. We also highlight new information achieved using a selective analytical technique to measure intact oxaliplatin in pharmacokinetic studies (comprising intravenous, intraperitoneal, and intrahepatic administration) and compare to results obtained by measurements of total platinum. The use of selective analytical techniques is strongly recommended giving kinetic parameters of the parent compound and not only to a complex mixture of platinum containing endogenous compounds.
Jerremalm
Elin
E
Karolinska Pharmacy, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Wallin
Inger
I
Ehrsson
Hans
H